Incyte Announces Positive Results from a Phase 2 Study of ...

The study met its primary endpoint, demonstrating that significantly more patients treated with ruxolitinib cream for 24 weeks achieved a ≥50 percent ...

Incyte Announces Positive 52-Week Results From a Randomized ...

The safety and efficacy of ruxolitinib cream are being evaluated in an Incyte -sponsored randomized, double-blind, dose-ranging, vehicle-controlled, Phase 2 ...

Incyte Announces New Data from Phase 2 Study Evaluating ...

“The results presented today reinforce the efficacy and safety profile of ruxolitinib cream, which shows great potential for people living with ...

Incyte Announces Positive 52-Week Data from Phase 2b Study ...

Results showed that treatment with oral povorcitinib was associated with substantial total body and facial repigmentation across all treatment ...

Incyte Announces Positive Data from Phase 2b Trial of Ruxolitinib ...

“The positive results of this Phase 2 study demonstrate the potential of ruxolitinib cream to offer a novel, effective non-steroidal topical ...

Incyte Presents New Late-Breaking Data from Phase 2 Study ...

10, 2024-- Incyte (Nasdaq:INCY) today announced results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (INCB54707), an ...

Incyte Announces 52-Week Results from Phase 2 Study Evaluating ...

10, 2023-- Incyte (Nasdaq:INCY) today announced new 52-week results from a Phase 2 study evaluating the efficacy and safety of povorcitinib ( ...

Incyte Announces Positive Interim Data from Phase 2 Trial of ...

“We are pleased to share updated interim results from our ongoing FIGHT-202 trial at ESMO , which underscore the potential of pemigatinib as an ...

Incyte Announces New Data from Phase 2 Study Evaluating ...

Incyte (INCY) announces positive results from a Phase 2 study on ruxolitinib cream for hidradenitis suppurativa at AAD Annual Meeting. The study ...

Incyte (INCY) Announces Positive Results From Vitiligo Study

Moreover, the overall efficacy and safety profile of ruxolitinib cream is consistent with the previously reported phase II data and no new ...

Syndax and Incyte Announce Positive Topline Results from the ...

Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease.

Incyte Announces Positive Updated Results from Phase 2 Trial of ...

Data presented at ESMO support the planned submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for pemigatinib before ...

Incyte Announces Positive 52-Week Results From a Randomized ...

Incyte today announces positive 52- week results from its randomized, double-blind, dose-ranging, Phase 2 study evaluating ruxolitinib cream, a nonsteroidal ...

Incyte Announces Positive Results from Phase 3 TRuE-V Program ...

Incyte (Nasdaq:INCY) today announced positive topline results from its pivotal Phase 3 TRuE-V clinical trial program evaluating the safety ...

Incyte Announces Positive Interim Data from Phase 2 Trial of ...

My husband had great partial response to Pemigatinib: I believe he had the best result of all on the trial.

Incyte Highlights Growth Opportunities and Provides Business ...

Notably, Incyte announces that the primary endpoint was met in its randomized, placebo-controlled, Phase 2 study evaluating the safety and ...

Incyte Announces Positive Topline Results from Phase 3 Trial ...

Incyte (Nasdaq:INCY) announced positive results from its Phase 3 TRuE-AD3 study evaluating ruxolitinib cream in children with atopic dermatitis.

Incyte Releases Q2 2024 Financials and Key Clinical Updates

Incyte announced positive topline results from two Phase 3 clinical studies evaluating retifanlimab (Zynyz®) in squamous cell anal carcinoma ...

Incyte Announces New Data from Phase 2 Study Evaluating ...

"The results presented today reinforce the efficacy and safety profile of ruxolitinib cream, which shows great potential for people living with ...

Incyte Reports 2023 Second Quarter Financial Results and Provides ...

"We continue to advance multiple programs in our pipeline, and recently announced positive topline results for two high potential programs, ...